Ligand Pharmaceuticals Among 3 Stocks Possibly Trading Below Intrinsic Value Estimates

Yahoo

4 days ago

As the Nasdaq reaches record highs driven by surges in chip stocks and Apple, while the S&P 500 shows signs of losing momentum, investors are keenly observing market fluctuations influenced by tariff concerns and economic health. In such a climate, identifying stocks that may be trading below their intrinsic value can offer potential opportunities for those looking to invest wisely amidst these complex conditions.
Top 10 Undervalued Stocks Based On Cash Flows In The United States
Name
Current Price
Fair Value (Est)
Discount (Est)
StoneCo (STNE)
$13.50
$26.82
49.7%
Similarweb (SMWB)
$7.56
$14.88
49.2%
Old National Bancorp (ONB)
$20.47
$40.10
49%
MNTN (MNTN)
$24.98
$49.17
49.2%
Ligand Pharmaceuticals (LGND)
$146.32
$290.34
49.6%
Kyndryl Holdings (KD)
$30.18
$59.38
49.2%
Fiverr International (FVRR)
$22.91
$45.03
49.1%
BioLife Solutions (BLFS)
$20.64
$40.11
48.5%
Berkshire Hills Bancorp (BHLB)
$24.04
$46.58
48.4%
Atlantic Union Bankshares (AUB)
$31.39
$62.54
49.8%
Click here to see the full list of 167 stocks from our Undervalued US Stocks Based On Cash Flows screener.
We're going to check out a few of the best picks from our screener tool.
Ligand Pharmaceuticals
Overview: Ligand Pharmaceuticals Incorporated is a biopharmaceutical company that develops and licenses biopharmaceutical assets globally, with a market cap of approximately $2.75 billion.
Operations: Ligand Pharmaceuticals generates revenue through the development and licensing of biopharmaceutical assets on a global scale.
Estimated Discount To Fair Value: 49.6%
Ligand Pharmaceuticals appears undervalued, trading at US$146.32, significantly below its estimated fair value of US$290.34. Recent financial results show a turnaround with Q2 net income of US$4.85 million from a previous loss, and raised 2025 revenue guidance to US$200-225 million. The company has also secured new revenue streams through royalties and milestone payments from ZELSUVMI's launch, enhancing cash flow prospects despite slower overall revenue growth compared to the broader market expectations.
According our earnings growth report, there's an indication that Ligand Pharmaceuticals might be ready to expand.
Take a closer look at Ligand Pharmaceuticals' balance sheet health here in our report.
Global-E Online
Overview: Global-E Online Ltd. operates a direct-to-consumer cross-border e-commerce platform across Israel, the United Kingdom, the United States, and other international markets, with a market cap of approximately $5.91 billion.
Operations: The company generates revenue of $796.77 million from its Internet Information Providers segment.
Estimated Discount To Fair Value: 27.9%
Global-E Online is trading at US$35.17, notably below its estimated fair value of US$48.75, highlighting potential undervaluation based on cash flows. Recent strategic partnerships with DHL and Shopify enhance its market position and revenue prospects, with earnings projected to grow 63.45% annually and expected profitability within three years. Despite a low forecasted return on equity of 16.6%, the company's revenue growth rate surpasses both industry and market averages, reinforcing its attractive valuation profile amidst robust expansion plans.
The growth report we've compiled suggests that Global-E Online's future prospects could be on the up.
Click to explore a detailed breakdown of our findings in Global-E Online's balance sheet health report.
Warner Music Group
Overview: Warner Music Group Corp. is a music entertainment company operating in the United States, the United Kingdom, Germany, and internationally with a market cap of approximately $15.66 billion.
Operations: Warner Music Group generates revenue through its Recorded Music and Music Publishing segments, with the former focusing on recorded music sales, streaming, licensing, and artist services while the latter involves licensing compositions for use in recordings, public performances, and related rights.
Estimated Discount To Fair Value: 10.3%
Warner Music Group trades at US$31.15, slightly below its estimated fair value of US$34.73, indicating potential undervaluation based on cash flows. Despite recent earnings showing a net loss of US$16 million for Q3 2025, the company maintains a robust growth forecast with earnings expected to rise by 21.53% annually over the next three years. Strategic initiatives like the joint venture with Bain Capital for music catalog acquisitions may bolster long-term cash flow prospects amidst high debt levels.
Upon reviewing our latest growth report, Warner Music Group's projected financial performance appears quite optimistic.
Get an in-depth perspective on Warner Music Group's balance sheet by reading our health report here.
Seize The Opportunity
Navigate through the entire inventory of 167 Undervalued US Stocks Based On Cash Flows here.
Shareholder in one or more of these companies? Ensure you're never caught off-guard by adding your portfolio in Simply Wall St for timely alerts on significant stock developments.
Streamline your investment strategy with Simply Wall St's app for free and benefit from extensive research on stocks across all corners of the world.
Contemplating Other Strategies?
Explore high-performing small cap companies that haven't yet garnered significant analyst attention.
Diversify your portfolio with solid dividend payers offering reliable income streams to weather potential market turbulence.
Fuel your portfolio with companies showing strong growth potential, backed by optimistic outlooks both from analysts and management.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Companies discussed in this article include LGND GLBE and WMG.
This article was originally published by Simply Wall St.
Have feedback on this article? Concerned about the content? with us directly. Alternatively, email [e-mail]